NCT03772353
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with more than 1 prior line of systemic treatment with Herceptin/trastuzumab regimen; Patients with a history of HER2 targeting tyrosine kinase inhibitors (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib); Patients who have previously received any CDK4/6 inhibitor treatment (e.g. Ibrance/palbociclib, Verzenio/abemaciclib, Kisqali/ribociclib); Patients with unstable symptomatic brain metastasis – see trial for details; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03772353